# Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium

> **NCT05718934** · PHASE4 · COMPLETED · sponsor: **Ciusss de L'Est de l'Île de Montréal** · enrollment: 144 (actual)

## Conditions studied

- Neuromuscular Blockade

## Interventions

- **DRUG:** Neostigmine and glycopyrrolate
- **DRUG:** Sugammadex

## Key facts

- **NCT ID:** NCT05718934
- **Lead sponsor:** Ciusss de L'Est de l'Île de Montréal
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-08
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05718934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05718934, "Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05718934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*